Navigation Links
Lymphoma Treatment May Harm, Halt Men's Sperm Production
Date:7/25/2014

FRIDAY, July 25, 2014 (HealthDay -- Treatment for lymphoma may lower men's fertility, new research indicates.

Both Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of the body's white blood cells, often affect young people who are still in their reproductive years. For men, treatment for these cancers can harm or halt sperm production. Although most men regain their fertility within two years of treatment, the researchers cautioned that men should be counseled about the possibility of this significant side effect before treatment begins.

"While many men can look forward to their fertility returning after treatment is over, not all will be so fortunate," Dr. Rebecca Sokol, president of the American Society for Reproductive Medicine, said in a society news release. "It is imperative that prior to the initiation of therapy, counseling and sperm preservation be made available to all lymphoma patients and their partners who may want to have children in the future."

In conducting the study, the researchers monitored the sperm of lymphoma patients undergoing various treatments to determine how each therapy affected the men's fertility. Specifically, they examined the sperm of 57 Hodgkin lymphoma patients and 18 non-Hodgkin lymphoma patients who used a sperm bank before starting their cancer treatment.

The researchers analyzed the men's sperm before treatment began as well as at three months, six months, 12 months and 24 months after treatment ended. The patients' sperm were compared to the sperm of 257 healthy, fertile men.

Even before treatment, the sperm of the men with lymphoma were more damaged than that of their healthy peers. These levels of damage improved between three and six months after treatment, but were still worse than the men in the control group.

Depending on their diagnosis, the men received combination chemotherapy, with or without radiation. Following treatment, their sperm density, total count, motility and vitality dropped. The lowest levels occurred three and six months after treatment.

The study, published recently in the journal Fertility and Sterility, revealed that alkylating chemotherapy was more often associated with a total halt in sperm production or a longer period of time for sperm production to resume. Alkylating chemotherapy damages DNA as it attacks cancer cells, to keep the cells from reproducing.

For all the men who received non-alkylating chemotherapy, with or without radiation, sperm production recovered between 12 to 24 months after treatment ended.

Two years after treatment ended, the researchers noted that sperm production had not recovered for 7 percent of the men in the study.

More information

The American Cancer Society provides more information on lymphoma.

SOURCE: The American Society for Reproductive Medicine, news release, July 22, 2014

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Protein may represent a switch to turn off B cell lymphoma
2. Researchers make promising discovery in pursuit of effective lymphoma treatments
3. New drug strategy attacks resistant leukemia and lymphoma
4. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
5. Limited Radiation May Help Some Kids With Lymphoma
6. Progress in quest to reduce use of radiation in treatment of pediatric Hodgkin lymphoma
7. New drug dramatically improves survival in Hodgkin lymphoma patients
8. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
9. New research seeks to improve survival for myeloma and lymphoma patients
10. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
11. Many options, good outcomes, for early-stage follicular lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lymphoma Treatment May Harm, Halt Men's Sperm Production
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... new market research report "Pharmaceutical Packaging Equipment Market by ... Labeling & Serialization), by Product Type (Tablet, Powder, Cream, ... published by MarketsandMarkets, studies the global market during the forecast ... to grow at a CAGR of 6.9% during the ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... , February 10, 2016 ... Medicine, Targeted Therapeutics and Companion Diagnostic Market to ... Participants, and Environment" research report indicates that the ... $149 billion by 2020 growing at a CAGR ... companion diagnostics and targeted therapeutics and is dominated ...
Breaking Medicine Technology: